


# ADT plus radiotherapy ups survival in metastatic prostate CA

27 June 2016



alone," the authors write. "Prospective trials evaluating local therapies for mPCa are warranted."

Several authors disclosed financial ties to the biopharmaceutical industry.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

(HealthDay)—For men with metastatic prostate cancer (mPCa), overall survival (OS) is improved for those treated with androgen deprivation therapy (ADT) and prostate radiotherapy (RT), compared with ADT alone, according to a study published online June 20 in the *Journal of Clinical Oncology*.

Chad G. Rusthoven, M.D., from the University of Colorado School of Medicine in Aurora, and colleagues examined the OS of [men](#) with mPCa treated with ADT, with and without prostate RT, using data from the National Cancer Database. A total of 6,382 men with mPCa were identified, of whom 8.4 percent received prostate RT.

At a median follow-up of 5.1 years, the researchers found that the addition of prostate RT to ADT correlated with improved OS on univariate analysis (P

"In this large contemporary [analysis](#), men with mPCa receiving prostate RT and ADT lived substantially longer than men treated with ADT

APA citation: ADT plus radiotherapy ups survival in metastatic prostate CA (2016, June 27) retrieved 25 October 2022 from <https://medicalxpress.com/news/2016-06-adt-radiotherapy-ups-survival-metastatic.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*